Clincosm LogoSign in Get a demo

Vascular Inflammation Stratified by Body Size Phenotype

Sponsor
Korea University (Other)
Overall Status
Completed
CT.gov ID
NCT01979068
Collaborator
(none)
250
Enrollment
1
Location

Study Details

Study Description

Brief Summary

  • Vascular Inflammation is a key factor in both the pathogenesis and outcome of atherosclerosis. 18FDG-PET is a promising novel tool for identifying and quantifying vascular inflammation within atherosclerotic plaque

  • Recently, unique subsets of obese individuals, such as metabolically obese but normal weight (MONW) and metabolically healthy obese (MHO), have been getting an attention

  • Therefore, the purpose of this study is to examine the relationship of vascular inflammation,measured by FDG-PET, with various body sized phenotypes

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    250 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Study Start Date :
    Mar 1, 2008
    Actual Primary Completion Date :
    Mar 1, 2011

    Outcome Measures

    Primary Outcome Measures

    1. max TBR values stratified by the four body size phenotypes [12 weeks]

    Secondary Outcome Measures

    1. Framingham risk scores according to the four body size phenotypes [12 weeks]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Healthy patients for visiting routine medical check in our clinic
    Exclusion Criteria:

    • history of CVD (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)

    • stage 2 hypertension (resting blood pressure, ≥160/100 mmHg)

    • history of inflammatory conditions that affect the study results

    • taking medications that might affect inflammatory status, including steroid and non-steroidal anti-inflammatory drug within 6 months

    • or malignancy or severe renal or hepatic disease

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Korea University Guro Hospital Seoul Korea, Republic of

    Sponsors and Collaborators

    • Korea University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    K. M. Choi, Professor, Korea University
    ClinicalTrials.gov Identifier:
    NCT01979068
    Other Study ID Numbers:
    • PET_MONW
    First Posted:
    Nov 8, 2013
    Last Update Posted:
    Nov 8, 2013
    Last Verified:
    Nov 1, 2013
    Additional relevant MeSH terms:
    Atherosclerosis
    Metabolic Syndrome

    Study Results

    No Results Posted as of Nov 8, 2013